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Telomeres protect chromosome ends from being
recognized as sites of DNA damage. Upon telomere
shortening or telomere uncapping induced by loss of
telomeric repeat-binding factor 2 (TRF2), telomeres
elicit a DNA-damage response leading to cellular
senescence. Here, we show that following TRF2
depletion, the levels of the long noncoding RNA
TERRA increase and LSD1, which binds TERRA, is
recruited to telomeres. At uncapped telomeres,
LSD1 associates with MRE11, one of the nucleases
implicated in the processing of 30 telomeric G over-
hangs, andwe show that LSD1 is required for efficient
removal of these structures. The LSD1-MRE11 inter-
action is reinforced in vivo following TERRAupregula-
tion in TRF2-deficient cells and in vitro by TERRA-
mimicking RNA oligonucleotides. Furthermore, LSD1
enhances the nuclease activity of MRE11 in vitro.
Our data indicate that recruitment of LSD1 to depro-
tected telomeres requires MRE11 and is promoted
by TERRA. LSD1 stimulates MRE11 catalytic activity
and nucleolytic processing of uncapped telomeres.
INTRODUCTION
Telomeres are the nucleoprotein caps that protect the ends of
linear chromosomes from being recognized as sites of DNA
damage (de Lange, 2009). Due to the end-replication problem
and nucleolytic processing, gradual attrition of telomere length
occurs with aging (Baird, 2008). The proper maintenance of telo-
meres is crucial for chromosome stability. Loss or damage of the
chromosome ends initiates a DNA-damage response (DDR) and
triggers replicative senescence (d’Adda di Fagagna et al., 2003;
Deng et al., 2008; Denchi and de Lange, 2007; Takai et al., 2003).
Mammalian telomeres consist of double-stranded 50-TTAG
GG-30/50-CCCTAA-30 repeats terminating in 30 protruding sin-
gle-stranded G-rich overhangs. Telomeric DNA is associated
with specialized telomeric proteins that are known as shelterinsC(de Lange, 2005). Shelterins play crucial roles in protecting chro-
mosome ends fromDNA-damage checkpoint signaling and DNA
repair (de Lange, 2009). Telomeric repeat-binding factors 1 and 2
(TRF1 and TRF2) bind directly the double-stranded telomeric
DNA recruiting TIN2, TPP1, and Rap1 to telomeres (de Lange,
2005). POT1 in association with its binding partner TPP1 binds
the single-stranded 30 G-rich overhangs (Baumann and Cech,
2001). TRF2-depleted telomeres as well as critically short telo-
meres elicit a robust ATM-mediated DDR (Denchi and de Lange,
2007; Karlseder et al., 1999; Okamoto et al., 2013), which in-
volves formation of ‘‘telomere dysfunction-induced foci’’ (TIFs)
(Takai et al., 2003). TRF2-depleted telomeres undergo telomere
fusion events by nonhomologous end-joining (NHEJ) (Celli and
de Lange, 2005). It has been proposed that TRF2-mediated
capping involves formation of t loop structures in which the telo-
meric 30 G overhang is tucked into the double-stranded part of
the telomeric DNA (Griffith et al., 1999). Consistent with this
notion, t loop formation depends on TRF2 (Doksani et al., 2013).
Telomere end fusions upon TRF2 removal are induced by
NHEJ and require prior removal of the telomeric 30 G overhangs
(Celli and de Lange, 2005; van Steensel et al., 1998). G overhang
removal involves at least two protein complexes with nuclease
activity: XPF/ERCC1 and MRE11/RAD50/NBS1. XPF-deficient
human cells have diminished G strand overhang loss upon
expression of the dominant-negative TRF2DBDM allele, and
Ercc1/ mouse embryonic fibroblasts (MEFs) are protected
from telomere end fusions upon expression of Trf2DBDM (Zhu
et al., 2003). Cells from the hypomorphic mouse mutant
Mre11ATLD1/ATLD1, which have defects in the ATM-dependent
DDR, retain G strand overhangs upon deletion of Trf2 and have
reduced chromosome end fusions (Attwooll et al., 2009). This
effect can be explained by the necessity of checkpoint activation
to promote NHEJ at uncapped telomeres (Denchi and de Lange,
2007). However, in the presence of the presumed nuclease-defi-
cient Mre11H129N allele, which is proficient in checkpoint
signaling, 30 G strand overhangs were also retained in Trf2-
deleted cells. This therefore indicates that in addition to its roles
in ATM activation, the nuclease activity of MRE11 is required for
telomere 30 end processing (Deng et al., 2009a).
Although tightly packaged as heterochromatin, telomeres are
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repeats, referred to as TERRA. TERRA is an RNA polymerase II
(RNAPII) transcript conserved throughout eukaryotes. It is tran-
scribed from subtelomeres toward chromosome ends (Azzalin
et al., 2007; Schoeftner and Blasco, 2008). TERRA remains
partly associated with telomeric chromatin and is regulated in
a cell-cycle-dependent manner, with low levels occurring in
late S phase (Azzalin et al., 2007; Deng et al., 2009b; Feuerhahn
et al., 2010; Porro et al., 2010). The nonsense-mediated mRNA
decay (NMD) factors regulate TERRA presence at telomeres
(Azzalin et al., 2007). TERRA transcription has been linked to
chromatin structure. TERRA expression is repressed by the
DNA methyltransferase enzymes DNMT1 and DNMT3b, which
methylate CpG dinucleotides present in the human subtelomeric
region (Nergadze et al., 2009; Yehezkel et al., 2008). Moreover,
also the SUV39H1 H3K9 histone methyltransferase and hetero-
chromatin protein 1a (HP1a), which binds H3K9me3, negatively
regulate TERRA transcription (Arnoult et al., 2012). TERRA has
been implicated in telomere length control. TERRA binds and
represses telomerase (Redon et al., 2010; Schoeftner and
Blasco, 2008), but this effect can be alleviated by TERRA binding
proteins (Redon et al., 2013). Induction of TERRA in Saccharo-
myces cerevisiae leads to telomere shortening in cis through
stimulation of exonuclease I (ExoI) rather than through inhibition
of telomerase (Pfeiffer and Lingner, 2012). Furthermore, TERRA
foci in S. cerevisiae can trigger the assembly of telomerase into
large clusters prior to their recruitment to short telomeres (Cusa-
nelli et al., 2013). TERRA has also been proposed to regulate the
exchange of RPA by POT1 at single-stranded telomeric DNA at
the end of S phase (Flynn et al., 2011).
Lysine-specific demethylase 1 (LSD1) (also known as KDM1
and AOF2) is an amine oxidase that catalyzes lysine demethyla-
tion in a flavin adenine dinucleotide (FAD)-dependent oxidative
reaction (Lan et al., 2008; Shi et al., 2004). LSD1 removes
mono- and dimethyl groups from lysine 4 (H3K4) (Shi et al.,
2004) and lysine 9 (H3K9) (Metzger et al., 2005) of histone 3.
LSD1 also acts on nonhistone proteins including p53, E2F1,
and DNMT1 (Huang et al., 2007; Kontaki and Talianidis, 2010;
Wang et al., 2009).
Here, we discover that TERRA collaborates with LSD1 and
MRE11 at uncapped telomeres. Upon TRF2 depletion, TERRA
expression increases, and LSD1 is tethered to telomeres.
LSD1 recruitment to dysfunctional telomeres requires the MRN
complex and is stimulated by TERRA, which associates with
LSD1 and enhances the binding affinity between LSD1 and
MRE11. LSD1 has no visible impact on the chromatin state of
uncapped telomeres, but it is required for the nucleolytic removal
of the telomeric 30 G overhang. Because LSD1 stimulates
MRE11 nuclease activity in vitro, it may promote removal of 30
G overhangs at dysfunctional telomeres through MRE11 in vivo.
Our data indicate that TERRA and LSD1 cooperate to regulate
MRE11 activity for the processing of uncapped telomeres.
RESULTS
Telomere Deprotection Modulates TERRA Association
with LSD1
Telomere uncapping induced by TRF2 knockdown leads to
TERRA upregulation in human fibroblasts (Caslini et al., 2009).766 Cell Reports 6, 765–776, February 27, 2014 ª2014 The AuthorsWe observed that also in HeLa cells, functional small hairpin
RNA (shRNA)-mediated depletion of TRF2 (Figures S1A and
S1B) leads to TERRA accumulation (Figure 1A, lower panel).
Because TERRA may participate in telomeric heterochromatin
formation (Arnoult et al., 2012; Deng et al., 2009b), we hypothe-
sized that it might assemble chromatin-modifying complexes at
dysfunctional telomeres in analogy to other long noncoding
RNAs like Xist and HOTAIR, which also regulate chromatin
(Penny et al., 1996; Tsai et al., 2010; Wutz et al., 2002). In order
to identify chromatin-remodeling complexes that are associated
with TERRA, we performed native RNA immunoprecipitation
experiments with several RNA binding proteins and chromatin-
modifying enzymes (data not shown). Immunoprecipitation of
endogenous LSD1 from HEK293T and HeLa cells specifically
retrieved endogenous TERRA, but not U2 small nuclear RNA
(snRNA) or 18S rRNA (Figures S1C and S1D, lower panels).
Because a substantial fraction of TERRA interacts with hnRNP
A1 (Redon et al., 2013), immunoprecipitation of endogenous
hnRNP A1 was used as positive control (Figure S1C, lower
panel). To rule out potential nonspecific interactions and to
determine whether the association between TERRA and LSD1
was not occurring postlysis in nuclear extracts, we further per-
formed analogous RNA immunoprecipitation experiments with
formaldehyde-crosslinked HeLa cells followed by stringent
washing conditions. Consistent with a bona fide interaction, we
observed that 2%–3% of TERRA was immunoprecipitated with
antibodies against endogenous LSD1, whereas TERRA did not
immunoprecipitate with IgG control (Figure 1A, lower panel).
Several cytoplasmic, mitochondrial, and nuclear RNAs
were not associated with LSD1 as assessed by RNA immu-
noprecipitation of crosslinked extracts (Figure S1E, lower panel),
whereas HOTAIR, which was previously shown to be associated
with LSD1-containing complexes (Tsai et al., 2010), served as a
positive control (Figure S1E, lower panel). Although the fraction
of TERRA bound by LSD1 was similar in wild-type (WT) cells
(shEV) and cells depleted for TRF2 (shTRF2), the absolute
amounts of TERRA-LSD1 complexes increased upon TRF2
removal, presumably due to the higher levels of TERRA that
became available for binding to LSD1 (Figure 1A, lower panel).
To further confirm the specificity of the association between
LSD1 and TERRA, we ectopically expressed HA-tagged LSD1
from transiently transfected plasmids in HEK293T cells (Fig-
ure 1B). Approximately 2% of TERRA was specifically immuno-
purifiedwith HA-tagged LSD1, whereas no TERRAwas detected
in extracts derived from empty vector control cells incubated
with HA antibody (Figure 1B, lower panel). For all these experi-
ments, the levels of recovered proteins with respect to the input
confirmed an efficient immunoprecipitation (Figures 1A, 1B, and
S1C–S1E, upper panels). Notably, the percentage of TERRA that
associates with LSD1 is comparable to the fraction of TERRA
bound to TRF1 and TRF2 (Deng et al., 2009b). Together, these
experiments indicate that TERRA is associated with LSD1
in vivo.
LSD1 Binds the UUAGGG Repeat Array of TERRA
Transcripts through Its SWIRM/AOL-N-ter Domain
To determine whether LSD1 interacts with TERRA directly and
to assess sequence requirements, we carried out RNA
Figure 1. LSD1 Binds TERRA In Vivo and In Vitro
(A) Western blotting was used to evaluate immunoprecipitation (IP) efficiency of endogenous LSD1 in RNA-IP experiments (upper panel). RNA-IP assays with an
antibody against endogenous LSD1 were performed in HeLa cells transfected with control vector (shEV) or depleted for TRF2 (shTRF2). IP-recovered RNA was
detected with probes annealing with TERRA or 18S rRNA (lower panel). IB, immunoblot.
(B) Western blotting was used to evaluate immunoprecipitation efficiency of ectopic HA-LSD1 in RNA-IP experiments (upper panel). RNA-IP assays with HA
antibody were performed in HEK293T cells transfected with HA-tagged LSD1 or expression vector alone. IP-recovered RNAwas detected with probes annealing
with TERRA or 18S rRNA (lower panel).
(C) Western blotting was used to detect the binding of LSD1, hnRNP A1, and hnRNP K in HeLa nuclear extracts to NeutrAvidin bead-bound biotinylated
(UUAGGG)3, (CCCUAA)3, TelBam3.4, or TelSau2.0 RNA oligonucleotides.
(D) Coomassie staining was used to detect His-LSD1 affinity purified from E. coli.
(E) Western blotting was used to evaluate the capturing of bacterial-expressed and Ni-NTA-purified His-LSD1 on bead-coupled (UUAGGG)3, (CCCUAA)3, or
subtelomeric sequences containing TelBam3.4 and TelSau2.0 RNA oligonucleotides.
EV, empty vector; HA, hemagglutinin; His, histidine. See also Figure S1.pull-down experiments. TERRA molecules consist of sub-
telomeric- and telomeric-derived sequences. Immobilized bio-
tinylated (UUAGGG)3 RNA oligonucleotide (TERRA), but not
antisense (CCCUAA)3 (ARRET) or subtelomeric sequences con-
taining RNA oligonucleotides (TelBam3.4 and TelSau2.0), re-
tained LSD1 from HeLa nuclear extracts (Figure 1C) and purified
His-LSD1 (Figures 1D and 1E). HnRNP K and hnRNP A1, which
bind to C-rich and G-rich RNAs (Burd and Dreyfuss, 1994;
Klimek-Tomczak et al., 2004; Thisted et al., 2001), respectively,
were detected as controls (Figure 1C).
We next delineated the TERRA interaction domains of LSD1.
Glutathione S-transferase (GST)-LSD1 fragments were ex-
pressed in E. coli, purified and incubated with bead-coupled
TERRA-mimicking oligonucleotides (UUAGGG)3 (Figures 2A–
2C). Full-length (FL) LSD1 and LSD1 fragments encompassing
the SWIRM and parts of the AOL domain (SWIRM/AOL-N-ter)
were retained on the beads specifically in the presence of
TERRA-mimicking (UUAGGG)3 oligonucleotides (Figure 2C).
The biochemical properties of the recombinant GST-SWIRM/
AOL-N-ter domain of LSD1were further characterized in electro-
phoretic mobility shift assays (EMSAs). The binding affinity of
purified LSD1 (Figure S2A) for RNA increased with oligonucleo-
tide length (Figure S2B). The dissociation constant of the RNA
binding domain of LSD1 for (UUAGGG)10 was 70 ± 1 nM (Figures
2D and 2E), whereas DNA of the same sequence was not bound
(Figure S2C). FL HA-tagged LSD1 had similar binding affinity forC(UUAGGG)10 as GST-LSD1 (1–382) (data not shown). Binding
specificity was further addressed by EMSA in competition
experiments in which the binding to labeled (UUAGGG)10/7
TERRA repeats was challenged with excess of unlabeled subte-
lomeric (Figure 2F) oligonucleotides or WT and mutant telomeric
repeats (Figure 2G). RNA oligonucleotides mimicking subtelo-
meric elements barely competed (Figure 2F), and LSD1 showed
specificity for the AGGG sequence within the UUAGGG repeats,
but it did not recognize the UU dinucleotide (Figure 2G). We
conclude that LSD1 associates directly via its SWIRM/AOL-N-
ter domain with TERRA, with moderate sequence specificity
for the WT UUAGGG repeat array of the transcript.
LSD1 Binding to Telomeres Is Increased upon TRF2
Depletion and Correlates with TERRA Levels
Because LSD1 associates with TERRA and because TERRA is a
component of telomeric chromatin (Azzalin et al., 2007), we
reasoned that LSD1 might also be physically bound to telo-
meres. To test this, we performed chromatin immunoprecipita-
tion (ChIP) experiments with an antibody against endogenous
LSD1 followed by dot blot analysis. We found telomeric DNA
but not centromeric DNA in association with LSD1 (Figures 3A
and 3B). The telomeric signal diminished upon shRNA-mediated
depletion of LSD1, confirming the specificity of the antibody (Fig-
ures 3A and 3B). Interestingly, the telomeric signal in the LSD1-
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Figure 2. LSD1 Preferentially Binds UUAGGG-TERRA Repeats
(A) Scheme of LSD1 deletion mutants.
(B) Ponceau staining was used to evaluate the expression of LSD1 deletion mutants.
(C) Western blotting was used to evaluate the binding of GST-LSD1 deletion mutants to NeutrAvidin bead-bound biotinylated (UUAGGG)3 oligonucleotide.
(D) Agarose EMSAwas used to measure LSD1 RNA binding activity in vitro. GST-LSD1 fragment D4 (aa 1–382) was assayed for binding to 32P-(UUAGGG)10 RNA
oligonucleotide.
(E) KD measurement of GST-LSD1 fragment D4 (aa 1–382) binding to
32P-(UUAGGG)10 RNA oligonucleotide. Exp1, experiment 1; Exp2, experiment 2; Exp3,
experiment 3.
(F) EMSA competition experiment with GST-LSD1 fragment D4 (aa 1–382) binding to 32P-(UUAGGG)10. The fold molar excess of added unlabeled (UUAGGG)10,
TelBam3.4-60-mer, and TelSau2.0-60-mer competitors is indicated at the top.
(G) EMSA competition experiment of GST-LSD1 fragment D4 (aa 1–382) binding to 32P-(UUAGGG)7 using (UUAGGG)7, (AAAGGG)7, (UUUCGG)7, and (UUAGCC)7
as competitors. Numbers indicate fold excess of competitor over 32P-labeled probe.
See also Figure S2.depletion (Figures 3A and 3B), suggesting that higher levels of
TERRA may enrich LSD1 at damaged chromosome ends. Since
RNAi-mediated TERRA downregulation cannot be employed in
our study because RNA oligonucleotides of telomeric sequence
may perturb telomere integrity by soaking up telomere-associ-
ated proteins, we sought to corroborate the link between TERRA
levels and LSD1 binding to chromosome ends in human colo-
rectal carcinoma HCT116 cells double knocked out (DKO) for768 Cell Reports 6, 765–776, February 27, 2014 ª2014 The Authorsthe DNA methyltransferases DNMT1 and DNMT3b (Rhee et al.,
2002), in which TERRA is highly expressed and remains associ-
ated with telomeric chromatin (Farnung et al., 2012). We infected
the parental (par) and the DKO cells with retroviruses expressing
a dominant-negative mutant of TRF2, TRF2DBDM, that strips
TRF2 and its interacting factors off the telomeres (van Steensel
et al., 1998; Zhu et al., 2000) and causes DDR activation, loss
of telomeric G overhangs, chromosome fusions, and genome
Figure 3. LSD1 Is Recruited to Uncapped Telomeres and Is Required for 30 G Overhang Removal
(A) ChIP of telomeric and centromeric DNA with LSD1 and gH2AX antibodies was performed in HeLa cells transfected with control vector (shEV) or depleted for
LSD1 (shLSD1), TRF2 (shTRF2), or both (shTRF2+shLSD1).
(B) Quantification of three different ChIP experiments represented by (A) (mean ± SD, n = 3). Statistical analysis was done using a two-tailed Student’s t test
(*p < 0.05).
(C) ChIP of telomeric and centromeric DNA with LSD1 and gH2AX antibodies was performed in HCT116 par and DNMT1 and DNMT3b DKO cells infected with
retroviruses expressing dominant-negative TRF2DBDM or empty vector.
(D) Quantification of three different ChIP experiments represented by (C) (mean ± SD, n = 3). Statistical analysis was done using a two-tailed Student’s t test
(**p < 0.01).
(E) Western blot analysis of HeLa cell extracts expressing shRNA constructs and shRNA-resistant forms of LSD1 WT and LSD1 K661A.
(F) TRF analysis was used to detect the telomeric 30 G overhang from HeLa cells transfected with the indicated plasmids. A radiolabeled telomeric probe was
annealed to native DNA detecting the single-strand (ss) telomeric signal (upper panel). ExoI (+ExoI) treatment removes the terminal telomeric 30 G overhang. The
total telomeric DNA is detected upon denaturation of the DNA (lower panel).
See also Figures S3 and S4.
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instability (de Lange, 2004; Karlseder et al., 1999, 2002; Smogor-
zewska et al., 2002; Stansel et al., 2001; van Steensel et al.,
1998). Compared to the par cells, which have longer telomeres
and low TERRA levels, DKO cells showed strongly enhanced
LSD1 recruitment upon expression of dominant-negative
TRF2DBDM (Figures 3C and 3D), thus supporting the notion that
TERRA may promote LSD1 binding to dysfunctional telomeres.
However, indirect effects due to the absence of the DNA meth-
yltransferases could not be excluded. For all these experiments,
the DNA-damage marker g-H2AX was monitored and served as
a control to evaluate the functional efficiency of TRF2 inactiva-
tion (Figures 3A–3D). Taken together, these data suggest that
LSD1 binds to chromosome termini and that TERRA upregula-
tion may enhance LSD1 recruitment in the context of dysfunc-
tional telomeres.
LSD1 Does Not Affect Telomeric Chromatin but Is
Required for the Processing of Uncapped Chromosome
Ends
LSD1 is known to demethylate the mono- and dimethyl forms
of lysine 4 (H3K4) (Shi et al., 2004) and 9 (H3K9) (Metzger
et al., 2005) of histone 3. Because LSD1 strongly associates
with dysfunctional telomeres, we investigated by ChIP a putative
role for LSD1 in controlling the histone methylation pattern upon
telomere uncapping (Figures S3A and S3B). The density of
mono- and dimethylated H3K4 across telomeres was not
affected following TRF2 depletion. On the contrary, dimethylated
H3K9 (H3K9me2) and, to amuch lesser extent, monomethylated
H3K9 (H3K9 me1) were decreased at chromosome ends upon
telomere uncapping, whereas they remained unaltered at
centromeric chromatin. However, the changes in the histone
methylation pattern at damaged telomeres appear not to rely
on LSD1 because the reduced density of mono- and dimethy-
lated H3K9 at dysfunctional telomeres was not rescued by
the concomitant depletion of TRF2 and LSD1 (Figures S3A
and S3B). Recently, it has been shown that LSD1 also controls
the methylation status of nonhistone proteins (Cho et al., 2011;
Huang et al., 2007; Kontaki and Talianidis, 2010; Wang et al.,
2009). To define a putative nonhistone LSD1 target at telomeres,
we examined whether telomeric phenotypes elicited upon
removal of TRF2 can be reversed by LSD1 depletion. Damaged
telomeres accumulate TIFs (Takai et al., 2003; Zhu et al., 2003).
TIF formation can be detected via the association of the
DNA-damage proteins gH2AX and 53BP1 with telomeres. In
immunofluorescence (IF)-fluorescence in situ hybridization
(FISH) experiments, we found that the DNA-damage marker
53BP1 accumulated with a similar frequency at telomeres of
TRF2-depleted and TRF2/LSD1 double-depleted cells (Figures
S3C and S3D). This indicates that TIF formation is not affected
by LSD1 in TRF2-deficient cells.
TRF2 removal leads to a rapid loss of the telomeric 30 G over-
hang signal and telomere fusions by NHEJ (Celli and de Lange,
2005; Zhu et al., 2003). Assessment of telomeric G overhang
by native in-gel hybridization revealed that the 30 G overhang
signal was reduced in TRF2-deficient cells as expected but
that it persisted upon concomitant depletion of TRF2 and
LSD1 (Figures 3E and 3F). Furthermore, expression of the
shRNA-resistant LSD1 WT, but not the demethylase-impaired770 Cell Reports 6, 765–776, February 27, 2014 ª2014 The Authorsmutant K661A (Lee et al., 2005) (Figure S4A), restored 30 G over-
hang processing in TRF2-depleted cells (Figures 3E and 3F).
Treatment with the 30 end-specific bacterial ExoI confirmed
that the detected single-stranded telomeric DNA was
terminal. These results were confirmed by analyzing the same
DNA samples in parallel (Figures S4B and S4C) by native
in-gel hybridization and an independent assay involving a
duplex-specific nuclease (DSN), which digests double-stranded
genomic DNA and leaves the single-stranded overhangs intact
(Zhao et al., 2011). The telomere single-strand G-rich overhang
was detected by Southern hybridization (Figure S4B). Also in
this assay, depletion of TRF2 reduced the G overhang signal,
whereas the signal was retained in TRF2 and LSD1 double-
depleted cells. Double depletion of TRF2 and MRE11 (Fig-
ure S4D) also did not lead to loss of the 30 Goverhang, consistent
with the fact that MRE11 is required for 30 G overhang removal
(Figure S4E). The LSD1 knockdown did not affect cell-cycle
progression (Figures S4F and S4G), ruling out the possibility
that the observed phenotype was due to alterations of the cell-
cycle profile. Despite the fact that removal of the 30 G overhang
is a prerequisite for NHEJ at chromosome ends (Zhu et al., 2003),
the frequency of telomere fusions observed in metaphase
spreads upon TRF2 depletion was not affected by LSD1 knock-
down (Figures S4H and S4I). This suggests that LSD1 depletion
may have slowed down but not prevented overhang removal.
Overall, these data indicate that LSD1, through its demethylase
activity, promotes G overhang resection at uncapped telomeres.
LSD1 Interacts with MRE11
We further reasoned that LSD1 may activate the MRE11 or
ERCC1/XPF nuclease to remove telomeric 30 G overhangs
from uncapped telomeres (Attwooll et al., 2009; Deng et al.,
2009a; Zhu et al., 2003). We tested for a physical interaction
between LSD1 andMRE11 by reciprocal coimmunoprecipitation
(Figures 4A and 4B). Proteins in HeLa cell nuclear extracts were
immunoprecipitated with antibodies against endogenous LSD1,
MRE11, or IgG, which served as negative control. We observed
that LSD1 specifically coimmunoprecipitated MRE11 and vice
versa, indicating that the two proteins can reside in the same
complex (Figure 4A). No interaction was found between endog-
enous LSD1 and XPF nor LSD1 and other proteins involved in 30
G overhang processing or in the activation of the telomeric DDR
(Figure S5). Notably, telomere uncapping by depletion of TRF2
increased the interaction between LSD1 andMRE11 (Figure 4A).
Furthermore, we found that also ectopically expressed HA-
tagged LSD1 and myc-tagged MRE11 associated in HEK293T
cells (Figure 4B). We next sought to identify the MRE11 domain
responsible for the interaction with LSD1.We generated different
GST-MRE11 deletionmutants (Figure 4C) and purified them from
recombinant E. coli. We then incubated glutathione agarose
beads-immobilized GST-MRE11 fragments with purified recom-
binant HA-tagged LSD1 in vitro. We found that HA-LSD1 inter-
acted with a C-terminal region of MRE11 encompassing the
GARmotif and amino acids adjacent to the DNA binding domain
(Figure 4D). On the other side, we performed an analogous
experiment to determine which domain of LSD1 is involved in
the interaction with MRE11. Purified GST-LSD1 fragments
were incubated with purified 33FLAG-MRE11. We observed
Figure 4. LSD1 Directly Interacts with MRE11
(A) Reciprocal coimmunoprecipitation assay was used to detect the interaction between endogenous LSD1 and MRE11 in HeLa transfected with control vector
(shEV) or depleted for TRF2 (shTRF2).
(B) Reciprocal coimmunoprecipitation assay was used to detect the interaction between ectopic HA-LSD1 and MRE11-myc in HEK293T cells.
(C) Scheme of MRE11 deletion mutants.
(D) Purified HA-LSD1 was incubated with the indicated glutathione bead-bound GST-MRE11 fragments. Western blotting was used to evaluate which GST-
MRE11fragment is able to retain HA-LSD1 in vitro.
See also Figure S5.that the SWIRM/AOL-N-ter domain of LSD1, responsible for the
interaction with TERRA (Figures 2A–2C), is also required for the
binding to MRE11 (Figures 5A and 5B). Thus, TERRA and
MRE11 associate with the same domain of LSD1 (Figure 5C).
TERRA Reinforces the Interaction between LSD1 and
MRE11
Next, we explored whether TERRA regulates the strength of
LSD1-MRE11 interaction. We carried out biochemical experi-
ments in which bead-bound GST-LSD1 was incubated with 33
FLAG-MRE11 in the presence of increasing amounts of
(UUAGGG)10 RNA oligonucleotide. TERRA-mimicking oligonu-
cleotide increased the amount of 33FLAG-MRE11 captured by
GST-LSD1 up to 9-fold (Figure 5D), whereas control oligonucle-
otide did not influence the binding (Figure S6A). Similarly, asso-
ciation of LSD1 and MRE11 was enhanced in HEK293T cells
transfected with (UUAGGG)10 TERRA but not with control RNA
oligonucleotides (Figure S6B). However, only LSD1 but not
MRE11 (data not shown) binds TERRA in a detectable manner,
suggesting that TERRA does not bridge their interaction.
LSD1 Associates with Dysfunctional Telomeres in an
MRN-Dependent Manner
Because MRE11 plays a critical role in sensing dysfunctional
telomeres by promoting the activation of ATM-dependent
DNA-damage signaling pathways, we further examined whether
the LSD1 binding to deprotected telomeres can be affected by
the MRN complex. For this purpose, we performed ChIP exper-
iments in TRF2-deficient cells depleted for MRE11 or NBS1
(Figure S6C), and we found that LSD1 no longer accumulatedCefficiently at damaged chromosome ends (Figures 5E and 5F).
Therefore, the MRN complex is critical for LSD1 retention at
dysfunctional telomeres. On the other hand, LSD1 did neither
affect the binding of MRE11 to telomeres (Figures S6D–S6F)
nor the formation of the MRN complex (Figure S6G).
LSD1 Stimulates MRE11 Nuclease Activities In Vitro
MRE11 exhibits exonuclease activity on DNA double-stranded
blunt end and 30-recessed substrates as well as endonuclease
activity on hairpin substrates (Paull and Gellert, 1998). In order
to test for effects of LSD1 on MRE11 nuclease activity, we
carried out in vitro assays (Lee et al., 2003). We purified WT
and the presumed nuclease-deficient MRE11H129N mutant
(Deng et al., 2009a) from human HEK293T cells (Figure 6A) and
measured exo- and endonuclease activities. MRE11 WT but
not the H129N mutant exhibited exo- and endonuclease activity
as expected (Figures 6B and 6C). In order to evaluate a contri-
bution of LSD1, we expressed 33FLAG-tagged MRE11 in
HEK293T cells alone or in combination with HA-LSD1 WT or
HA-LSD1 K661A demethylation-impaired mutant (Lee et al.,
2005) (Figure 6D). When 33FLAG-MRE11 was purified from
HA-LSD1 WT-expressing cells, MRE11 showed an enhanced
exonuclease activity if compared to the MRE11 purified from
WT cells or from cells expressing catalytically impaired HA-LSD1
K661A (Figure 6E). A similar result was obtained when 33FLAG-
MRE11 and HA-LSD1 were purified separately and coincubated
in the nuclease assays (Figure S7A). Incubation of 33FLAG-
MRE11 with HA-LSD1 but not with BSA stimulated the MRE11
exonuclease activity (Figure S7B). Addition of a specific LSD1
inhibitor (Inhibitor IV; Calbiochem) reduced the LSD1-mediatedell Reports 6, 765–776, February 27, 2014 ª2014 The Authors 771
Figure 5. MRE11 Interacts with the SWIRM/AOL-N-ter Domain of LSD1, and TERRA Stabilizes the Interaction between the Two Proteins
(A) Scheme of LSD1 deletion mutants.
(B) Western blotting was used to evaluate the binding of GST-LSD1 deletion mutants to purified 33FLAG-MRE11.
(C) Scheme of the interaction domains required for the association of LSD1 with TERRA and MRE11.
(D) Binding of affinity-purified 33FLAG-MRE11 to glutathione bead-bound GST-LSD1 fragment D4 (aa 1–382) or GST in the presence of increasing amounts of
(UUAGGG)10.
(E) ChIP of telomeric and centromeric DNA with LSD1 and gH2AX antibodies was performed in HeLa cells transfected with control vector (shEV) or depleted for
TRF2 (shTRF2), TRF2, and MRE11 (shTRF2+shMRE11) and TRF2 and NBS1 (shTRF2+shNBS1).
(F) Quantification of three different ChIP experiments represented by (E) (mean ± SD, n = 3). Statistical analysis was done using a two-tailed Student’s t test
(*p < 0.05).
F, FLAG. See also Figure S6.stimulation of MRE11 (Figure S7C). Furthermore, LSD1 WT
and, to a lesser extent, LSD1 K661A enhanced also the
MRE11 endonuclease activity (Figure 6F). Altogether, these
findings demonstrate that LSD1 stimulates the exo- and endonu-
clease activities of MRE11.
DISCUSSION
In this study, we identify TERRA and LSD1 as actors at de-
protected telomeres that follow TRF2 depletion, and we provide
evidence that TERRA and LSD1 collaborate with MRE11 in the
processing of the 30 G overhangs. Our results demonstrate that
MRE11 as part of the MRN complex is required for LSD1 stabi-
lization at uncapped telomeres. We demonstrate that LSD1772 Cell Reports 6, 765–776, February 27, 2014 ª2014 The Authorsdirectly interacts with MRE11 and that the SWIRM/AOL-N-ter
domain of LSD1 mediates the binding to the C-terminal region
of MRE11 encompassing the GAR motif. We also provide
evidence that TERRA promotes the interaction between LSD1
and MRE11. First, increased TERRA levels upon TRF2 depletion
correlate with enhanced LSD1 recruitment at dysfunctional
telomeres in HeLa cells. Second, enhanced TERRA levels in
HCT116 DKO versus HCT116 WT cells correlate with increased
LSD1 recruitment upon telomere uncapping. Third, and most
strikingly, TERRA strongly enhances the binding affinity between
MRE11 and LSD1 in vitro with purified proteins and in vivo upon
transfection of TERRA RNA oligonucleotides. We also find that
LSD1 but not MRE11 binds TERRA. Therefore, TERRA seems
not to bridge their interaction. However, when associated with
Figure 6. LSD1 Stimulates the MRE11 Exo- and Endonuclease
(A) Coomassie staining was used to detect 33FLAG-MRE11 WT and H129N
affinity purified from HEK293T cells.
(B) Exonuclease assays were performed with increasing concentrations (2, 4,
10, and 20 nM) of 33FLAG-MRE11 WT or H129N mutant, purified from
HEK293T.
(C) Endonuclease assays were performed with increasing concentrations
(12.5, 25, 50, and 100 nM) of 33FLAG-MRE11 WT or H129N mutant, purified
from HEK293T.
(D) Coomassie staining was used to detect 33FLAG-MRE11 WT co-
transfected with empty vector, HA-LSD1 WT, or HA-LSD1 K661A plasmids.
Immunoprecipitated material from HEK293T cells transfected with empty
vector only was used as negative control.
(E) Exonuclease assays were performed with increasing concentrations (2, 4,
10, and 20 nM) of 33FLAG-MRE11WT cotransfected or not with HA-LSD1WT
or HA-LSD1 K661A catalytically impaired mutant.
(F) Endonuclease assays were performed with increasing concentrations
(12.5, 25, 50, and 100 nM) of 33FLAG-MRE11 WT cotransfected or not with
HA-LSD1 WT or HA-LSD1 K661A catalytically impaired mutant.
See also Figure S7.
Figure 7. Proposed Model for the Function of TERRA and LSD1 at
Uncapped Telomeres
Depletion of TRF2 leads to increased TERRA levels and recruitment of LSD1 to
uncapped telomeres. LSD1 recruitment requires MRE11 and may be pro-
moted by TERRA, which enhances the affinity between LSD1 and MRE11.
LSD1 stimulates the exo- and endonuclease activities of MRE11. LSD1
recruitment to uncapped telomeres triggers removal of the telomeric 30 G
overhang through MRE11 and possibly other LSD1 substrates.
CLSD1, the negatively charged phosphate-sugar backbone
of TERRA might attract the abundant arginine residues of
the GAR domain in MRE11 (Figure 7). Alternatively, TERRA
might have allosteric effects on LSD1 increasing its affinity for
MRE11.
TERRA directly interacts with the SWIRM/AOL-N-ter domain
of LSD1. The SWIRM domain is found in several chromatin-
modifying complexes (Nicholson and Chen, 2009) and has
been implicated in binding nucleosomal and free double-
stranded DNA. However, the SWIRM domain of LSD1 lacks
DNA binding activity (Yoneyama et al., 2007), and our results
indicate that it contributes to directly bind RNA. Our mutational
analyses reveal that perturbation of the AGGG sequence within
the UUAGGG repeats strongly reduces the association between
TERRA and LSD1, thus suggesting that LSD1 can bind unfolded
UUAGGG repeats. However, because the UUAGGG repeats of
TERRA can fold into parallel-stranded G quadruplex structures
(Martadinata et al., 2011; Martadinata and Phan, 2013; Xu
et al., 2010), it is possible that LSD1 instead recognizes
TERRA quadruplexes. LSD1 complexes were previously found
in association with the long noncoding RNA HOTAIR, but this
interaction appeared to be indirect because purified LSD1
lacked HOTAIR binding activity (Tsai et al., 2010). Thus, we
report here direct LSD1-RNA interaction.
What are the roles of LSD1 at uncapped telomeres? We find
that LSD1 is required for efficient resection of the 30 G overhang
at dysfunctional telomeres because its depletion leads to persis-
tence of the 30 G overhang in TRF2-depleted cells. Our results
also indicate that LSD1 exerts its effects on the 30 G overhang
through MRE11 (Figure 7). Strikingly, LSD1 stimulates the
endo- and exonuclease activities of MRE11 when coexpressed
with MRE11 in HEK293 cells prior to purification of MRE11 or
when added to the in vitro reaction. The lysine demethylation
activity of LSD1 appears involved in the stimulation of MRE11
because K661A mutant LSD1 had a reduced ability to activate
MRE11 in vitro and telomeric 30 G overhang removal in vivo.ell Reports 6, 765–776, February 27, 2014 ª2014 The Authors 773
Similarly, addition of the LSD1 small molecule inhibitor reduced
the stimulatory effects of LSD1. This suggests that MRE11
may contain methylated lysine residues that inhibit its activity.
Unexpectedly, LSD1 depletion did not affect the frequency of
telomere fusions upon TRF2 depletion in our experiments. 30 G
overhang removal must precede telomere end-joining by the
NHEJ machinery (Zhu et al., 2003). We therefore suspect that
LSD1 depletion does slow down but not completely abolish
the resection of 30 G overhang at uncapped telomeres. In this
scenario, not 30 G overhang removal but other steps in the reac-
tion are rate limiting for the end-joining of uncapped telomeres
such as chromosome end apposition, which becomes rate
limiting upon loss of 53BP1 (Dimitrova et al., 2008). While this
paper was under review, LSD1 was reported to also associate
with internal sites of DNA damage, reducing H3K4 dimethylation
and slightly affecting the DDR (Mosammaparast et al., 2013).
However, DNA end processing was not assessed in this paper,
and at telomeres, contrary to chromosome internal damage
sites, LSD1 depletion has no notable effects in histone methyl-
ation and 53BP1 recruitment.
In summary, our study provides mechanistic clues into how
the MRN complex and TERRA synergize for stabilizing the bind-
ing of LSD1 at dysfunctional chromosome ends. LSD1 interacts
with and activates MRE11 nuclease activities. This step seems
crucial because LSD1 is required for the efficient removal of
the 30 telomeric G overhang though additional activities of
MRE11, or different substrates of LSD1 might also contribute
to end processing of uncapped telomeres (Figure 7). The here-
describedmechanismmodulates the response to local telomeric
DNA damage that occurs upon TRF2 loss, but the same mech-
anisms may apply during cellular senescence, aging, and acci-
dental or pathological telomere dysfunction events.
EXPERIMENTAL PROCEDURES
Plasmids
shRNA vectors were prepared by cloning double-stranded DNA oligonucleo-
tides into pSuper-Puro or pSuper-Blast. The target sequences were as
follows: TRF2, 50-GCGCATGACAATAAGCAGA-30; LSD1, 50-GCACCTTATAA
CAGTGATA-30; MRE11, 50-TGAGAACTCTTGGTTTAAC-30; and NBS1, 50-AG
GAAGATGTCAATGTTAG-30. FL human MRE11 and LSD1-coding sequences
were cloned from cDNAs into pCDNA6-based mammalian expression vectors
using PCR amplification and In-Fusion cloning (Clontech Laboratories). The FL
LSD1 cDNA fragment was subsequently transferred to bacterial expression
plasmids pET30a and pGEX6p-1 for His-tagged and GST-tagged LSD1 FL
production. pGEX6p1-LSD1 K661A and pCDNA6-HA-LSD1 K661A were
obtained using the QuikChange Site-Directed Mutagenesis Kit (Stratagene).
MRE11 and LSD1 fragments were cloned into pGEX6p1 bacterial expression
vector using PCR amplification and In-Fusion cloning.
Cell Culture and Transfection
HeLa cells were transfected using Lipofectamine 2000 according to the
manufacturer’s protocol (Invitrogen). Puromycin (2 mg/ml; InvivoGen) or blasti-
cidin (10 mg/ml; InvivoGen) was added to themedium 24 hr after transfection of
pSuper-Puro constructs. Puromycin and blasticidin selection was maintained
for 4 days.
RNA-IP
RNA-IP assays were performed as described previously by Deng et al.
(2009b). More detailed procedures are described in Supplemental Experi-
mental Procedures.774 Cell Reports 6, 765–776, February 27, 2014 ª2014 The AuthorsChromatin Immunoprecipitation
ChIP assays were performed as described previously by Abreu et al. (2010).
More detailed procedures are described in Supplemental Experimental
Procedures.
EMSA
EMSA for 33FLAG-MRE11 was performed as described before by Lee et al.
(2003). EMSA for GST-LSD1 (aa 1–382) was performed with the following
modifications. 13 EMSA reaction buffer for GST-LSD1 (aa 1–382) was
composed of 25 mM Tris-HCl (pH 8.0), 100 mM NaCl, 10% glycerol, 2 mM
MgCl2, 1 mM DTT, and 1 U/ml SUPERase-IN. A total of 1 nM of
32P-gATP 50
end-labeled RNA or DNA oligonucleotide probes wasmixed with the indicated
proteins and competitor oligonucleotides and incubated to equilibrium for
30 min at 37C. The reaction was supplemented with EMSA loading buffer
to a final concentration of 13 (8% glycerol, 2 mM Tris-HCl [pH 7.5], 0.02%
bromophenol blue, and cyan cyanol) and separated on 2% 0.53 TBE agarose
gels at 60 mA for 30 min. Gels were dried, exposed to Phosphorimager
screens, and analyzed using a FLA-3000 Phosphorimager (Fujifilm) and
AIDA Image Analyzer software (Raytest).
TRF Analysis and G Overhang Analysis
Following phenol extraction and ethanol precipitation, genomic DNA was
digested with RsaI and HinfI and resolved by pulse-field gel electrophoresis
on 1% agarose in 0.53 TBE at 5 V cm1 for 16 hr at 14C with switch times
ramped from 0.5 to 6 s. For G overhang analysis, the gel was dried (50C)
and hybridized under native conditions (50C) for detection of ss telomeric
DNA, before denaturation and a second hybridization for total telomeric
DNA. For washes, gels were rinsed in 43 SSC and incubated for 30 min at
room temperature, followed by successive 30 min washes at 50C in 43
SSC/0.5%SDSand 23SSC/0.5%SDS. The 32P-labeled telomeric DNA probe
was generated as follows: a templatemixture of 1- to 5-kb-long telomeric DNA
fragments was synthesized by ligating double-stranded telomeric DNA oligo-
nucleotides ((TTAGGG)5, (CCCTAA)5) that were amplified by PCR. The probe
was random labeled with a-32P-dCTP and cold dTTP and dATP (for detection
of the TTAGGG strand).
DSN Assay and G Overhang Analysis
Determination of the telomeric G overhang with the DSN method was done as
described previously by Zhao et al. (2011).
Protein Purification
HA-, 33FLAG-, GST-, or His-tagged constructs were purified using anti-HA,
M2, and GSH agarose (Sigma-Aldrich) or Ni-NTA agarose (QIAGEN). E. coli
strain Rosetta (DE3)pLysS (Novagen) was used for all protein expressions in
bacteria. Recombinant His-LSD1was purified using Ni-NTA agarose and imid-
azole competitor elution. GST-LSD1 FL and fragments as well as GST-MRE11
fragments were purified using GSH agarose and, if needed, eluted using
reduced glutathione. HA-LSD1 and 33FLAG-MRE11 were expressed in
HEK293T cells and purified using HA agarose (Sigma-Aldrich) or M2 agarose
followed by corresponding competitor peptide elution.
In Vitro MRE11 Nuclease Assays
MRE11 nuclease assays were performed as described by Lee et al. (2003) and
Park et al. (2011). Briefly, purified 33FLAG-MRE11 was preincubated with or
without purified HA-LSD1 or BSA and indicated inhibitors for 90 min at 37C
in nuclease reaction buffer (25 mM MOPS [pH 7], 100 mM NaCl, 1 mM
MnCl2, and 1 mM DTT), followed by addition of 1 nM of
32P end-labeled
nuclease substrate and further incubation overnight at 37C. Reaction prod-
ucts were analyzed on 15% denaturing polyacrylamide gels, fixed, exposed,
and signals revealed using the FLA-3000 Phosphorimager. The LSD1 inhibitor
was LSD1 inhibitor IV, RN-1,HCl from Calbiochem. The MRE11 inhibitor was
mirin from Sigma-Aldrich.
Antibodies
The following antibodies were used: 53BP1 (NB100-304; Novus Biologicals);
Co-REST (07-455; Millipore); Histone H3 (ab1791; Abcam); H3K4me1 (07-
436; Millipore); H3K4me2 (07-030; Millipore); H3K9me1 (ab9045; Abcam);
H3K9me2 (ab1220; Abcam); hnRNP A1 (4B10, sc-32301; Santa Cruz Biotech-
nology); hnRNP K (ab39975; Abcam); LSD1 (ab17721; Abcam); MRE11
(NB100-142; Novus Biologicals); NBS1 (NB100-143; Novus Biologicals);
phospho-H2AX (05-636; Millipore); and Rad50 (ab89; Abcam).
Microscopy
TIF analysis by IF-FISH staining was performed as described before (Celli and
de Lange 2005). FISH on metaphase spreads was performed as described
before (Azzalin et al. 2007).
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